2024-07-02 17:31:08
A file variety of purposes have been acquired within the preliminary public provide (IPO) of Techno Medication Restricted, which has accomplished the withdrawal of cash from the capital market by means of the e book constructing methodology. Towards Tk 100 crore that the corporate desires to gather from the capital market, Tk 2,487,18,104 purposes have been submitted, which is the best within the historical past of the inventory market.
This firm of the pharmaceutical sector received permission to withdraw 100 crores from the capital market. Eligible buyers participated within the bidding and set a cut-off value of Rs.34 per share.
The IPO value is mounted for normal buyers at 30 % lower than that i.e. 24 rupees. He utilized for the IPO from 9 to 13 June.
It’s recognized that the corporate will elevate capital of 100 crore by means of IPO. Towards Tk 100 crore of the corporate, by means of 102 crore 65 lakh 86 thousand 180 shares, 1 lakh 12 thousand 926 purposes have acquired Tk 2 thousand 487 crore 18 thousand 104 purposes.
Out of this, purposes of Tk 2,412,753,310 have been submitted from buyers. Functions of Tk 61 crore 17 lakh 57 thousand 194 have been acquired from eligible buyers.
The corporate will spend the cash raised by means of the IPO on buy of recent equipment, BMRE (Narsingdi plant), constructing development (Gazipur plant), partial debt compensation and difficulty administration bills.
In accordance with the corporate’s audited monetary statements for the monetary yr ended June 30, 2023, the web asset worth per share (NAVPS) together with revaluation was Tk 27 74 paise and with out revaluation it was Tk 22 57 paise. The Firm’s Earnings per Share (EPS) for the monetary yr underneath evaluation stood at Rs 2.8 paise, in comparison with a weighted common price of Rs 3.25 paise for the final 5 years.
Imperial Capital Restricted and EBL Investments Restricted are chargeable for managing the problem of the corporate.
Techno Medication Restricted is among the prime 5 corporations within the nation in pharmaceutical exports. The corporate has already gained a status by exporting medicines. The corporate manufactures and sells life-saving medicines and continues to be a worthwhile firm.
Techno Medication ranked fourth in drug exports in 2014. Then in 2015 and 2016, it gained the third place. Registered as a personal firm in 2009 and transformed from a personal firm to a public firm in 2019.
At current, the whole capital of the corporate is round 94 crores of which 88 % shares are held by the board of administrators together with 63 % of the managing director.
Techno medication are usually coping with specialised merchandise. The institute has oncology chemotherapy, anesthesia, contraception drugs, injections and state-of-the-art expertise implant stick (contraception for five years). Additionally contains Veterinary and Basic Human Medication.
Implant Stick which is the one techno medication producer in Bangladesh. It applies to contraception for five years. The corporate’s primary flagship medication are -Delivery Management Medication-Sukhi Third Era Oral Capsule, Provera Injection, Implant Stick (Delivery Management for five Years), Anticancer Medication-Heritin, Zolomid, Epocide, Anesthetic Medication-Lidosin Plus Injection, Vencurone 10TV Injection, Basic Human Medication-Motilex Suspension, Omicec, Romilec, Cefixone Injection, Veterinary Medication-Vermic Injection, Dexavate Injection, Rumen Plus Powder, Vita Zinc.